Biodesix is a fully integrated molecular diagnostics company advancing the development of products for personalized medicine. Biodesix developed, validated and commercialized VeriStrat®, a serum proteomic test currently available to help physicians guide therapy for patients with advanced non-small cell lung cancer. Samples are processed in Biodesix’ CLIA –certified laboratory and results are typically reported within 72 hours of sample shipment. VeriStrat is based on ProTS®, proprietary technology which harnesses the power of mass spectrometry and enables the discovery of specific molecular profiles that characterize a patient’s condition or likely outcome in response to therapy. Biodesix collaborates with clinical investigators to address critical clinical questions, and partners with biotechnology and pharmaceutical companies to develop diagnostics to select patients most likely to benefit from novel therapies. For more information about Biodesix, please visit www.Biodesix.com.